Adverse effects of amoxicillin may be potentially under-reported
the ONA take:
Amoxicillin is a widely used antibiotic in the penicillin group of drugs. It is used to treat bacterial infections in patients with cancer, and may be used as prophylaxis in some patients. In a systematic review, researchers conducted a review of controlled trials to assess potential harms related to amoxicillin use.
The review included a total of 45 trials, featuring a total of 10,519 participants. The researchers found that almost twice as many patients receiving amoxicillin had diarrhea compared with patients receiving placebo, and diarrhea was more than three times more likely among participants receiving amoxicillin-clavulanate. An association between candidiasis and amoxicillin-clavulanic acid use was also observed.
However, the authors acknowledge a limitation to their study. All the trials measured efficacy rather than harm as their primary outcome, and only 25 of the study included information on harms. Therefore, the number of harms reported was lower than expected, which contributed to a conclusion that harms may be under-reported in clinical trials. In a related commentary, clinicians are advised to be wary of the lack of information on potential adverse effects from amoxicillin.
Researchers conducted a review of controlled trials to assess potential harms related to amoxicillin use.
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- Refined Equation May Obviate Oncotype DX in Breast Cancer Treatment Decisions
- Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis
- Intermediate Oncotype DX Scores Prognostic of OS in Early-stage Breast Cancer
- Colorectal Cancer and Dietary Fiber: Source Is More Important Than Amount
- Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|